Irrespective of whether propofol use is growing in minimally invasive surgery, if the aim is to grab market share with a new, improved formulation of propofol, then ideally, you would want that formulation to be substitutable for propofol in any setting.
Even if Terumo had forged ahead with development, it was never AVE’s intention that TPM/propofol would be restricted to the Japanese market. Once the product was developed, AVE was aiming to license it out into other markets, especially the U.S.
What matters most at this time is that the new formulation passes toxicology.
- Forums
- ASX - By Stock
- The Countdown ...
Irrespective of whether propofol use is growing in minimally...
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $15.84M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $189.4K | 37.93M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
47 | 96459006 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 44667162 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
47 | 96459006 | 0.004 |
38 | 85474980 | 0.003 |
18 | 64435176 | 0.002 |
10 | 11005012 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 44667162 | 21 |
0.006 | 27552675 | 17 |
0.007 | 11272721 | 10 |
0.008 | 5987459 | 6 |
0.009 | 1840000 | 3 |
Last trade - 16.10pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
0.5¢ |
  |
Change
0.001 ( 11.1 %) |
|||
Open | High | Low | Volume | ||
0.5¢ | 0.5¢ | 0.5¢ | 18998000 | ||
Last updated 15.25pm 29/03/2024 ? |
Featured News
AVE (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online